An International Survey of the Diagnosis, Management, and Treatment of Hepatitis C in Patients with End-Stage Renal Disease

被引:0
|
作者
Olson, Mira R. [1 ]
Grewal, Kevin S. [1 ]
Bingaman, Adam
Zaki, Radi [1 ]
Stewart, Shelby [1 ]
Horton, John
Araya, Victor [1 ]
Ortiz, Jorge [1 ]
机构
[1] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA
关键词
Ribavirin; Interferon; Dialysis; Transplantation; VIRUS-INFECTION; METAANALYSIS; PREVALENCE; SURVIVAL;
D O I
暂无
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: Hepatitis C is one of the leading causes of death from liver disease in the United States, and is frequently associated with renal disease. Two major organizations-the American Association for the Study of Liver Disease and the National Kidney Foundation-have published recommendations regarding the treatment of hepatitis C in the presence of chronic kidney disease; however, these guidelines do not always provide the same recommendations. Given the paucity of data on adherence to the current guidelines, a survey was conducted to provide information about the current practices of physicians in comparison to the published guidelines. Materials and Methods: An observational study was conducted via a global survey asking physicians treating patients who had concurrent hepatitis C and chronic kidney disease. Results: The 218 questionnaires collected requested the physician's subspecialty, the number of transplants performed at the hospital, the usual method of screening for hepatitis C, the preferred route, the indication and frequency of liver biopsy, the use of ribavirin and interferon, the use of hepatitis-C-positive donors in kidney transplant, and consent requirements. Conclusions: Our results showed that many physicians do not follow current recommendations. We argue that a consensus group be formed to set forth guidelines for the management of hepatitis C to optimize outcomes, and improve overall morbidity.
引用
收藏
页码:203 / 213
页数:11
相关论文
共 50 条
  • [41] Hepatitis C and end-stage liver disease
    Settles D.M.
    Vinayek R.
    Current Hepatitis Reports, 2010, 9 (4) : 243 - 252
  • [42] Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease
    Pawa, Swati
    Ehrinpreis, Murray
    Mutchnick, Milton
    Janisse, James
    Dhar, Ravi
    Siddiqui, Firdous A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (11) : 1316 - 1320
  • [43] Nephrologists' Perceptions of Renal Transplant as Treatment of Choice for End-stage Renal Disease, Preemptive Transplant, and Transplanting Older Patients: An International Survey
    Ghahramani, Nasrollah
    Karparvar, Zahra Yeganeh
    Ghahramani, Mehrdad
    Shrivastava, Pritika
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2011, 9 (04) : 223 - 229
  • [44] Stability of end-stage renal disease patients' treatment decisions
    Gordon, EJ
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (06) : 3006 - 3009
  • [45] Hepatitis c and end stage renal disease: A global survey.
    Ortiz, Jorge A.
    Palma-Vargas, Juan M.
    Wright, Francis H.
    Membreno, Fernando E.
    Harrison, Stephen
    Foster, Preston F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 363 - 363
  • [46] Phosphorus management in end-stage renal disease
    Finn, WF
    SEMINARS IN DIALYSIS, 2005, 18 (01) : 8 - 12
  • [47] Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates
    Al-Rabadi, Laith
    Box, Terry
    Singhania, Girish
    Al-Marji, Catreena
    Agarwal, Adhish
    Hall, Isaac
    Gordon, Craig E.
    Tran, Huy
    HEMODIALYSIS INTERNATIONAL, 2018, 22 : S45 - S52
  • [48] Preventing hepatitis B and hepatitis C virus infections in end-stage renal disease patients: Back to basics
    Kellerman, S
    Alter, MJ
    HEPATOLOGY, 1999, 29 (01) : 291 - 293
  • [49] Iron management in end-stage renal disease
    Fishbane, S
    Maesaka, JK
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (03) : 319 - 333
  • [50] End-Stage Renal Disease: Medical Management
    Wouk, Noah
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (05) : 493 - 499